Holen Sie sich die Stockscreener-App
32.34
1.22%
-0.40
Handel nachbörslich:
32.26
-0.08
-0.25%
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA) - marketbeat.com
Ideaya enrolls first patient in phase 1 trial of KAT6/7 inhibitor - Investing.com Canada
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - TradingView
Breast to lung cancers: IDEAYA puts IDE574 into human testing - stocktitan.net
IDYA PE Ratio & Valuation, Is IDYA Overvalued - Intellectia AI
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo - Yahoo Finance
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses - Yahoo Finance
IDEAYA Biosciences, Inc. $IDYA Position Decreased by JPMorgan Chase & Co. - MarketBeat
IDEAYA Biosciences Achieves 119.91% Growth, Establishing It as a Multibagger in Biotechnology Sector - Markets Mojo
IDYA Stock Price, Quote & Chart | IDEAYA BIOSCIENCES INC (NASDAQ:IDYA) - ChartMill
IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history - Yahoo Finance UK
Block Trades: Does IDEAYA Biosciences Inc have a competitive edge2026 Key Highlights & Advanced Technical Analysis Signals - baoquankhu1.vn
Wedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA) - marketbeat.com
37,595 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Tudor Investment Corp ET AL - marketbeat.com
Price-Driven Insight from (IDYA) for Rule-Based Strategy - Stock Traders Daily
IDEAYA begins combination trial of IDE849 and IDE161 cancer drugs By Investing.com - Investing.com Canada
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma – Company Announcemen - Financial Times
IDEAYA Biosciences Opens Weak with 5.14% Gap Down Amid Market Concerns - Markets Mojo
Vanguard disaggregates holdings; affiliates to report separately (IDYA) - stocktitan.net
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Finviz
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and Incyte (INCY) - The Globe and Mail
Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness - simplywall.st
RBC Capital reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
RBC Capital reiterates Ideaya Biosciences stock rating on trial delay - Investing.com
Jefferies reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1%Here's Why - marketbeat.com
IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA) - marketbeat.com
Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing - Investing.com Canada
Citizens reiterates Ideaya Biosciences stock rating on mUM trial data By Investing.com - Investing.com Canada
Citizens reiterates Ideaya Biosciences stock rating on mUM trial data - Investing.com
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial - Sahm
IDEAYA delays darovasertib trial results to mid-April By Investing.com - Investing.com Canada
IDEAYA delays darovasertib trial results to mid-April - investing.com
Cancer trial readout nears as IDEAYA targets first-half April lock - stocktitan.net
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
(IDYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Barclays Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities - The Globe and Mail
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs – Company Announcement - Financial Times
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs - Barchart.com
IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP - MarketBeat
Iron Triangle Partners LP Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus - simplywall.st
IDEAYA Biosciences, Inc. $IDYA Position Increased by Baker BROS. Advisors LP - MarketBeat
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd - MarketBeat
Truist reiterates Ideaya Biosciences stock rating on MTAP program By Investing.com - Investing.com Canada
IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating - TipRanks
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update - Finviz
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial - GuruFocus
Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE892 - marketscreener.com
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892 - TradingView
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update – Company Announcement - Financial Times
IDEAYA Biosciences announces the latest development timeline for its Cdkn2a project - Bitget
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):